Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
Are there certain patient characteristics that drive you to recommend intralesional 5-FU or MTX for a large SCC on the back?
Related Questions
When do you recommend SRT, if ever, for small SCCs and BCCs?
Would you offer adjuvant immunotherapy in an elderly patient with stage IIB desmoplastic melanoma post resection with underlying autoimmune disease?
What is your experience with itraconazole as a primary or adjunct therapy for individuals with numerous BCCs?
Is narrow-band ultraviolet B (nbUVB) phototherapy contraindicated or recommended with caution in patients with a personal history of melanoma?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
What approach, or dosing interval, do you find is most effective reducing side effects of Hedgehog Inhibitors (i.e., vismodegib) for patients with numerous BCC?
How would you manage a large area of multiple, recurrent cutaneous squamous cell carcinomas of the scalp with ulcerations and non-healing areas despite cryotherapy, multiple Mohs procedures, and 5-FU?
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
What patient characteristics or clinical scenarios guide the decision in performing slow Mohs procedures?
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
